GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » Effective Interest Rate on Debt %
中文

ITeos Therapeutics (ITeos Therapeutics) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is ITeos Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. ITeos Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. ITeos Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $5.99 Mil. Therefore, ITeos Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.


ITeos Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for ITeos Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Effective Interest Rate on Debt % Chart

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - - - - -

ITeos Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ITeos Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, ITeos Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ITeos Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's Effective Interest Rate on Debt % falls into.



ITeos Therapeutics Effective Interest Rate on Debt % Calculation

ITeos Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (4.673+6.058)/ 2 )
=-1  *  0/5.3655
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.837 + 0.836
=4.673

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.807 + 1.251
=6.058

ITeos Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  0/( (5.929+6.058)/ 2 )
=-1  *  0/5.9935
=0.00 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.812 + 1.117
=5.929

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.807 + 1.251
=6.058

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


ITeos Therapeutics  (NAS:ITOS) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


ITeos Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics (ITeos Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Watertown, MA, USA, 02472
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Matthew Gall officer: Chief Financial Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Michel Detheux director, officer: Chief Executive Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Yvonne Mcgrath officer: VP, Research and Development C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Joanne Jenkins Lager officer: Chief Medical Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Detlev Biniszkiewicz director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Tony W Ho director CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Robert Iannone director 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950

ITeos Therapeutics (ITeos Therapeutics) Headlines